Skip to main navigation Skip to search Skip to main content

Mitochondrial Delivery of Therapeutic Agents by Amphiphilic DNA Nanocarriers

  • Miu Shan Chan
  • , Dick Yan Tam
  • , Ziwen Dai
  • , Ling Sum Liu
  • , Jonathan Weng Thim Ho
  • , Man Lee Chan
  • , Di Xu
  • , Man Shing Wong
  • , Chung Tin*
  • , Pik Kwan Lo
  • *Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

37 Citations (Scopus)

Abstract

The first example of mitochondrial delivery of the anticancer drug doxorubicin (Dox) is presented by lipid-functionalized DNA nanocages (LNCs). Dox localized in mitochondria induces significant cytotoxicity and cellular apoptosis in MCF-7 compared with Dox localized in lysosomes. These results suggest that LNC has the potential to be an outstanding tool in the treatment of specific organelle-related diseases such as cancers. Delivery of the anticancer drug doxorubicin to mitochondria by lipid-functionalized DNA nanocages (LNCs) is demonstrated for the first time. The results suggest outstanding potential for the use of LNCs as drug nanocarriers in treatments for organelle-specific diseases.

Original languageEnglish
Pages (from-to)770-781
Number of pages12
JournalSmall
Volume12
Issue number6
DOIs
Publication statusPublished - 10 Feb 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

User-Defined Keywords

  • anticancer drugs
  • delivery
  • DNA nanocarriers
  • lipophilic molecules
  • mitochondria

Fingerprint

Dive into the research topics of 'Mitochondrial Delivery of Therapeutic Agents by Amphiphilic DNA Nanocarriers'. Together they form a unique fingerprint.

Cite this